コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 to l-idonic acid and uses NADPH as preferred coenzyme.
2 drogenase to generate alanine with NADH as a coenzyme.
3 ith the 5'-deoxyadenosyl moiety of the B(12) coenzyme.
4 biosynthesis of this universally distributed coenzyme.
5 romatic dehalogenase that does not require a coenzyme.
6 forms, and in complex with the nicotinamide coenzyme.
7 DIP2A) is known to be involved in acetylated coenzyme A (Ac-CoA) synthesis and is primarily expressed
8 with inositol hexaphosphate (InsP6), acetyl-coenzyme A (AcCoA) and/or substrate Resistance to Ralsto
9 at catalyzes pyruvate's conversion to acetyl coenzyme A (AcCoA), thereby connecting these two pathway
10 ne residues by employing the cofactor acetyl-coenzyme A (AcCoA), thereby providing a dynamic control
12 ased levels of acetyl phosphate, acetoacetyl coenzyme A (acetoacetyl-CoA), butyryl CoA, acetoacetate,
14 Acetate and the related metabolism of acetyl-coenzyme A (acetyl-CoA) confer numerous metabolic functi
16 t can also catalyze the hydrolysis of acetyl-Coenzyme A (acetyl-CoA) in the absence of an arylamine s
20 rnative carbon source utilization for acetyl coenzyme A (acetyl-CoA) production and gluconeogenesis.
22 s cycle, glyoxylate is condensed with acetyl coenzyme A (acetyl-CoA) to give malate, which undergoes
23 te lyase (ACLY) synthesizes cytosolic acetyl coenzyme A (acetyl-CoA), a fundamental cellular building
24 d is sensitive to the availability of acetyl coenzyme A (acetyl-CoA), we investigated a role for meta
26 e, enabling biosynthesis of cytosolic acetyl coenzyme A (acetyl-CoA, the two-carbon isoprenoid precur
28 the transport of cytoplasmic long chain acyl-coenzyme A (acyl-CoA) into the mitochondrial matrix, whi
34 roduce mm flux through the key fluoromalonyl coenzyme A (CoA) building block, thereby offering the po
35 (OG) is a small molecule inhibitor of acetyl coenzyme A (CoA) carboxylase (ACC), the enzyme that cont
37 ly conserved ER protein FIT2 as a fatty acyl-coenzyme A (CoA) diphosphatase that hydrolyzes fatty acy
38 catalyzes the reduction of hydroxycinnamoyl-coenzyme A (CoA) esters using NADPH to produce hydroxyci
39 directed metabolic fluxes to generate acetyl-Coenzyme A (CoA) from glucose resulting in augmented his
40 nome of MLL-rearranged AML by linking acetyl-coenzyme A (CoA) homeostasis to Bromodomain and Extra-Te
42 DmdB, a 3-methylmercaptopropionate (MMPA)-coenzyme A (CoA) ligase, undergoes two sequential confor
43 ation of the meta-hydroxyl group of caffeoyl-coenzyme A (CoA) on the pathway to monolignols, with the
44 levels of intermediate and anaplerotic acyl-coenzyme A (CoA) species incorporated into the Krebs cyc
46 carbon-carbon bond forming step between acyl coenzyme A (CoA) substrates offer a versatile route for
47 rase superfamily member 2 (Them2) is an acyl-coenzyme A (CoA) thioesterase that catalyzes the hydroly
49 the ATP-dependent conversion of citrate and coenzyme A (CoA) to oxaloacetate and acetyl-CoA(1-5).
50 lysophosphatidylethanolamine (LPE) with acyl-coenzyme A (CoA), designated LYSOPHOSPHATIDYLETHANOLAMIN
52 ate generated during synthesis of fatty acyl-coenzyme A (CoA), the reaction catalyzed by an enzyme in
54 ing the final and committed step in the acyl-coenzyme A (CoA)-dependent biosynthesis of triacylglycer
56 ative abundance of the gene encoding butyryl-coenzyme A (CoA):acetate-CoA-transferase, a major enzyme
57 group of N(10)-formyl-THF to produce formyl-coenzyme A (formyl-CoA) as a central reaction intermedia
58 ts under regular 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin) treatm
59 Until recently, 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) have
61 The mevalonate [3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase] pathway synthesizes lipi
64 best inhibitors are competitive with acetyl coenzyme A and an X-ray cocrystal structure reveals that
66 amide synthase that uses C16 fatty acid acyl-coenzyme A and dihydroxy LCB substrates but increased ac
67 e enzyme phosphotransacylase (PTAC) recycles Coenzyme A and generates an acyl phosphate that can serv
69 he downstream metabolites, including malonyl-coenzyme A and palmitic acid, completely restored the in
72 s the polymerization of 3-(R)-hydroxybutyryl-coenzyme A as a means of carbon storage in many bacteria
73 eracting partner, Golgi adaptor protein acyl-coenzyme A binding domain containing protein 3 (ACBD3).
74 uncover that the Golgi resident protein acyl-coenzyme A binding domain-containing 3 (ACBD3) serves as
75 emperature as the different variants of acyl-coenzyme A binding protein have similar m-values when th
79 ctivated protein kinase activation of acetyl-coenzyme A carboxylase (ACC) and increased lipid content
81 ort into mitochondria via deletion of acetyl coenzyme A carboxylase 2 (ACC2) does not cause cardiomyo
83 in ACC2, encoding a plastid-targeted acetyl-coenzyme A carboxylase, cause hypersensitivity to specti
84 DI-010976, an allosteric inhibitor of acetyl-coenzyme A carboxylases (ACC) ACC1 and ACC2, reduces hep
85 h (enoyl-coenzyme A, hydratase/3-hydroxyacyl coenzyme A dehydrogenase)], and a marker of proximal tub
88 es, we conducted a mouse trial of a stearoyl-coenzyme A desaturase (SCD) inhibitor ("5b") that preven
90 abolism genes (fatty acid synthase, stearoyl-coenzyme A desaturase 1, and perilipin 2) was drasticall
91 uided mutational analyses suggests that acyl-coenzyme A enters the active site through the cytosolic
93 lism; this limits the availability of acetyl coenzyme A for histone acetylation at genes encoding inf
94 The biosynthesis of the major acyl carrier Coenzyme A from pantothenic acid (PA) is critical for su
96 interestingly, we also identified endogenous coenzyme A glutathione disulfide (CoA-S-S-G) in tissue f
97 razinamide (PZA), interrupts biosynthesis of coenzyme A in Mycobacterium tuberculosis by binding to a
102 o and activated the promoters of 4-coumarate:coenzyme A ligase genes (Os4CL3 and Os4CL5) resulting in
103 that the gene encoding a specific cinnamate coenzyme A ligase likely obtained its new function follo
106 tion, we cloned and characterized a caffeoyl-coenzyme A O-methyltransferase (PhCCoAOMT1) from the pet
107 ed protein (Adrp), whereas it augmented acyl-coenzyme A oxidase 1 (Acox-1), proliferator-activated re
108 s and in vivo rescue potential of the acetyl-Coenzyme A precursor S-acetyl-4'-phosphopantetheine as a
109 One therapeutic strategy is to generate Coenzyme A precursors downstream of the defective step i
111 in Npc1a weakens the ability of ectopic HMG Coenzyme A reductase (Hmgcr) to induce germ cell migrati
112 thway upstream of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), the target of statins.
113 ubiquitination of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), which catalyzes a rate-lim
116 ncoding PCSK9 and 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR; the target of statins) as i
117 AHA/ACC) changed 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitor (statin) eligibility crit
118 indications for 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitor (statin) therapy than mid
119 es of the influence of hydroxymethylglutaryl-coenzyme A reductase inhibitors (also known as statins)
120 ering properties, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have broad ant
124 inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway to protect against infectio
125 non-initiation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase therapy in patients with cirrhosis
126 roxylase) and ccr1g (deficient for cinnamoyl-coenzyme A reductase) lines, albeit to a lower extent.
127 by inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, are among the most widely prescrib
128 family B member 1, peroxisomal trans-2-enoyl-coenzyme A reductase, phospholipase A2 receptor, protein
129 emia, inhibit the 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme of de nov
130 ically inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase, which is a rate-limiting enzyme fo
132 he genes encoding 3-HYDROXY-3-METHYLGLUTARYL-COENZYME A REDUCTASE1 (HMGR1) and MAKIBISHI1, the rate-l
136 ein-based model for the NiP center of acetyl coenzyme A synthase using a nickel-substituted azurin pr
137 nic genes such as 3-hydroxy-3-methylglutaryl-coenzyme A synthase, fatty acid synthase, and stearoyl-C
144 ctroscopy, the cutin mutants long-chain acyl-coenzyme A synthetase2 (lacs2), permeable cuticle1 (pec1
145 talyze the sequential esterification of acyl-coenzyme A thioesters to the R4, R3, R3', and R2 positio
146 lyse the transfer of an acyl group from acyl-coenzyme A to cholesterol to generate cholesteryl ester,
147 ons suggested that SvBAHD05 is a p-coumaroyl coenzyme A transferase (PAT) mainly involved in the addi
149 ith the high carbon efficiency drive, acetyl-coenzyme A was entirely produced using the carbon-effici
150 1) and CER3 catalyzes the conversion of acyl-Coenzyme A's to alkanes with strict substrate specificit
151 lytic transport involving sliders (including coenzyme A) picking up, transporting and selectively del
152 tins, or HMG CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase inhibitors, are drugs with multipl
153 e oxidation to fuel the production of acetyl coenzyme A, acetylation of histones and induction of gen
155 th 3,5-dihydroxybenzoic acid, ATP, malonate, coenzyme A, and the malonyl-CoA ligase MatB, venemycin p
156 y acid-binding protein 1), and Ehhadh (enoyl-coenzyme A, hydratase/3-hydroxyacyl coenzyme A dehydroge
157 ctly dependent on metabolites such as acetyl-coenzyme A, S-adenosylmethionine, and NAD+, among others
158 onverted to the central intermediate benzoyl-coenzyme A, which is enzymatically reduced to cyclohexa-
159 used cysteine to synthesize glutathione and coenzyme A, which, together, down-regulated ferroptosis.
160 re, we identify the PO membrane protein acyl-coenzyme A-binding domain protein 5 (ACBD5) as a binding
162 rrier protein) synthase (ACPS) catalyzes the coenzyme A-dependent activation of apo-ACPP to generate
163 wo separable mechanisms: dampening of acetyl-coenzyme A-dependent carbon metabolism through histone h
169 ress the cholesterol-esterifying enzyme acyl-coenzyme A:cholesterol acyltransferase (ACAT1), but not
170 sterol O-acyltransferase 1 (also named acyl-coenzyme A:cholesterol acyltransferase, ACAT1) transfers
171 -acyltransferase (MBOAT) enzyme family, acyl-coenzyme A:cholesterol acyltransferases (ACATs) catalyse
172 of increased or decreased expression of ACYL-COENZYME A:DIACYLGLYCEROL ACYLTRANSFERASE1 (DGAT1) or PH
173 one (line CL37) or together with castor acyl:coenzyme A:diacylglycerol acyltransferase2 reduced HFA a
174 eneration (PKAN) and result in low levels of coenzyme-A (CoA) in the CNS due to impaired production o
175 rget of pitavastatin, hydroxymethylglutarate coenzyme-A reductase (HMGCR), was found to be over-expre
178 structures reveals that upon binding to the coenzyme and substrate, the active pocket of BmLDH under
180 irst study to report identification of major coenzymes and antioxidants and quantify them, simultaneo
182 )H NMR experiment can simultaneously measure coenzymes and antioxidants in extracts of whole human bl
184 e and evaluate important metabolites such as coenzymes and antioxidants that are present at high conc
185 methionine and in a large range of essential coenzymes and cofactors and is therefore essential for a
186 for major macromolecules are calculated, 2) coenzymes and inorganic ions are identified and their st
187 attachment of NAD(+)-glycerol dehydrogenase coenzyme-apoenzyme complex onto supporting gold electrod
188 e find that blocking the entry of fatty acyl coenzyme As (CoAs) into peroxisomal beta-oxidation in th
189 zymes (NAD(+), NADH, NADP(+), NADPH), energy coenzymes (ATP, ADP, AMP), antioxidants (GSH, GSSG), and
190 l for human metabolism, the organocobalamins coenzyme B12 and methylcobalamin, are highly photolabile
191 mation of an inactive dimer, alter substrate/coenzyme binding, or impair structural stability of HSD1
193 icotinamide adenine dinucleotide (NAD(+)), a coenzyme essential for DNA repair, glycolysis, and oxida
194 ybdopterin-based two-electron reduction, two coenzyme F(420)-based hydride transfers, and one coenzym
197 PH-binding site and was dependent on reduced coenzyme F420 (F420H2), a stronger reductant with a mid-
198 t amino acids as well as rare cofactors like coenzyme F420 The latter likely accounts for the strong
200 e proteins that catalyse the biosynthesis of coenzyme F430 from sirohydrochlorin, termed CfbA-CfbE, a
202 The enzyme uses an ancillary factor called coenzyme F430, a nickel-containing modified tetrapyrrole
206 otinamide adenine dinucleotide (NAD(+)) is a coenzyme for redox reactions, making it central to energ
208 The ability to visualize the ubiquitous coenzymes fundamental to cellular functions, simultaneou
212 ide adenine dinucleotide (NADH)-an important coenzyme in living cells-generating NAD(*) radicals with
213 er-soluble B-complex vitamin, functions as a coenzyme in macronutrient oxidation and in the productio
214 B(1) is well-characterized for its role as a coenzyme in metabolic pathways, particularly those invol
215 Adenine Dinucleotide (NADH) is an important coenzyme in the human body that participates in many met
217 on, where her work on the role of folic acid coenzymes in one-carbon metabolism revealed the mechanis
218 ow immobilization of anionic nucleotides and coenzymes, in addition to charge- and size-selective cap
219 of Phe 34 can influence the position of the coenzyme, indicating a new regulatory mechanism involvin
220 macromolecules (DNA, RNA, proteins), lipids, coenzymes, inorganic ions and species-specific component
222 ide adenine dinucleotide (NAD), a ubiquitous coenzyme, is required for many physiological reactions a
229 ry of the methanogenesis gene cluster methyl-coenzyme M reductase (Mcr) in the Bathyarchaeota, and th
230 rding to the well-accepted mechanism, methyl-coenzyme M reductase (MCR) involves Ni-mediated thiolate
234 h archaeal methane/alkane metabolism, methyl-coenzyme M reductase (Mcr), in metagenome-assembled geno
235 ailable metagenomes for homologues of methyl-coenzyme M reductase complex (MCR), we have obtained ten
236 engineered archaeal strain to produce methyl-coenzyme M reductase from unculturable anaerobic methano
237 genesis in methanogens is mediated by methyl-coenzyme M reductase, an enzyme that is also responsible
238 s that are necessary for a functional methyl-coenzyme M reductase, and all subunits were detected in
239 s that are necessary for a functional methyl-coenzyme M reductase, and all subunits were detected in
240 ated in the methylation of Arg-285 in methyl coenzyme M reductase, binds a methylcobalamin cofactor r
242 genes involved in carbohydrate transport or coenzyme metabolism were duplicated, likely facilitating
243 substrates with extended carbon chains and a coenzyme moiety-unusual for a thiolase-are unknown.
245 A, and endogenous CoA-S-S-G along with redox coenzymes (NAD(+), NADH, NADP(+), NADPH), energy coenzym
248 cells exhibited elevated levels of the redox coenzyme nicotine adenine dinucleotide (NAD+), elevated
249 dinucleotide phosphate (NADP(+) and NADPH); coenzymes of energy including adenosine triphosphate (AT
251 slational modification or the recruitment of coenzymes or metal ions to achieve catalytic function.
254 are involved in metabolism of oxidoreduction coenzymes, purine ribonucleoside triphosphate, ATP and p
255 d that individuals with mutations in COQ6, a coenzyme Q (also called CoQ(10), CoQ, or ubiquinone) bio
256 d its human homolog ALDH3A1 to mitochondrial coenzyme Q (CoQ) biosynthesis, an essential pathway disr
257 d by defects in Complex III (CIII) activity, coenzyme Q (CoQ) biosynthesis, and mitochondrial calcium
258 mitochondrial matrix octapeptidase Oct1p and coenzyme Q (CoQ) biosynthesis-a pathway essential for mi
259 roton leak in Fmr1 KO mitochondria caused by coenzyme Q (CoQ) deficiency and an open cyclosporine-sen
264 n which the intra-mitochondrial synthesis of coenzyme Q (ubiquinone, Q) and Q levels are profoundly d
268 functions as an oxidoreductase that reduces coenzyme Q(10) (CoQ) (also known as ubiquinone-10), whic
269 fying diseases displaying chronic low plasma Coenzyme Q(10) (CoQ) values may be important to prevent
270 n and a consequent increase in the levels of coenzyme Q(10), an endogenous lipophilic antioxidant.
271 SP1 is mediated by ubiquinone (also known as coenzyme Q(10), CoQ(10)): the reduced form, ubiquinol, t
273 product, the mitochondrial electron carrier coenzyme Q, both in cultured cancer cells and tumors.
279 nts (dexamethasone (DX), melatonin (MEL) and coenzyme Q10 (CoQ10)) in a single formulation (DMQ-MSs)
282 one, coenzyme Q10, or idebenone (a synthetic coenzyme Q10 homolog), as well as inhibition of oxidativ
284 pplement (vitamins A, C, and E; carotenoids; coenzyme Q10) both before and during treatment was assoc
285 , including conjugated fatty acids, sterols, coenzyme Q10, and lipophilic vitamins, such as vitamins
286 eactive oxygen species, such as glutathione, coenzyme Q10, or idebenone (a synthetic coenzyme Q10 hom
288 ial phosphatase regulator of biosynthesis of coenzyme Q6 (ubiquinone or CoQ6) and a mitochondrial red
291 energy exploitation including photocatalytic coenzyme regeneration, templating, and carbon nitride ba
292 etics are excellent analogues of the natural coenzymes, revealed also in crystal structures of the en
296 ve a dose-dependent response to nicotinamide coenzymes, such as the reduced form of nicotinamide aden
298 rely on unstable and expensive nicotinamide coenzymes that have prevented their widespread exploitat